INTRODUCTION
Cancers of the nasal and paranasal sinuses are rare, aggressive tumors that generally are diagnosed at an advanced stage because patients often remain asymptomatic until the tumor becomes large enough to manifest symptoms. 1 Although surgery is the mainstay of treatment for patients with these tumors, 2 to the best of our knowledge there is limited scientific rationale and weak clinical evidence supporting treatment guidelines in this field. Therapy encompassing a multimodality approach has been shown to improve treatment outcomes. [3] [4] [5] [6] [7] [8] Although it has been established that maximal safe surgical resection yields the best overall survival (OS) outcomes, 2 the role of postoperative radiotherapy is less well defined in the treatment of this disease. Some older series found no survival benefit with adjuvant therapy, [9] [10] [11] whereas others demonstrated that combined radiotherapy and surgery yield better survival rates. [3] [4] [5] [6] [7] Older radiotherapy techniques most likely contributed to the lack of therapeutic advantage to chemoradiotherapy, as demonstrated by the high rates of severe long-term toxicities. 7 Significant treatment-related toxicity is less common with modern radiotherapy techniques. It is interesting to note that recent advances in radiotherapy have demonstrated significantly improved outcomes with minimal long-term toxicity. 3, [12] [13] [14] [15] [16] The optimal sequencing of chemotherapy and radiotherapy for patients with sinonasal carcinoma remains controversial. 17 Small reports have shown a benefit for induction chemotherapy, 8, [18] [19] [20] [21] [22] and numerous institutional and multiinstitutional series have shown a benefit for adjuvant therapy. [3] [4] [5] [6] 8, 23 To our knowledge, definitive concurrent chemoradiotherapy has been less studied in this disease, with a few series demonstrating low survival outcomes and in-field failures with biologically equivalent doses <65 grays. 24 Comparisons of surgery with or without adjuvant chemoradiotherapy reported in retrospective series have emphasized the importance of surgical resection. 25 Similarly, other series have shown surgery followed by radiotherapy to be superior to radiotherapy alone. 26, 27 However, the small cohorts in these retrospective series coupled with heterogeneous histologies significantly limit the broad application of these findings.
In the current study, we used the high number and breadth of cases available in the National Cancer Data Base (NCDB) to investigate outcomes in a modern patient cohort. We specifically examined the presenting characteristics of these tumors according to histology and subsite and compared outcomes by treatment modality for squamous cell carcinomas (SCC). To the best of our knowledge, this is the largest and most comprehensive assessment of sinonasal malignancies reported to date.
MATERIALS AND METHODS
The deidentified NCDB was used for the current study. The NCDB collects data from >1500 community and academic cancer centers and has been reported to represent approximately 70% of all cancer cases in the United States. The NCDB is the result of a collaboration between the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used, or the conclusions drawn from these data by the investigator. The NCDB has established criteria to ensure the data submitted meet specific quality benchmarks. The following NCDB analysis was performed with the approval of our local Institutional Review Board.
We queried the deidentified NCDB file for all patients with primary sinonasal malignancies diagnosed between 2004 and 2012 based on primary site codes C300 to C319 (ICD-0-3). This included the following subsites for initial analysis: maxillary sinus, ethmoid sinus, frontal sinus, sphenoid sinus, nasal cavity, paranasal sinuses, and middle ear. As detailed in Figure 1 , our approach to develop a comprehensive and complete cohort for multivariate analysis (MVA) eliminated multiple subsites from our analysis. Ultimately, the subsites included on MVA were maxillary sinus, ethmoid sinus, and nasal cavity. For tumor (T) and lymph node (N) classification, clinical staging information was used primarily when available; otherwise pathologic staging information was applied. Metastases at the time of diagnosis were determined from provided overall stage and "CS mets at diagnosis." Overall stage was derived from TNM stages using the seventh edition of the AJCC staging manual. 28 "Microscopic residual tumor," "macroscopic residual tumor," and "residual tumor, NOS [not otherwise specified]" were categorized as positive surgical margins. The additional variables accounted for in the primary analysis included age, sex, race/ethnicity, year of diagnosis, specific disease site, Charlson/Deyo combined comorbidity score (CDCC), 29, 30 and therapy received. We included the following histologies for our initial analysis of presentation and outcomes: SCC, adenosquamous carcinoma, adenocarcinoma, esthesioneuroblastoma, sinonasal undifferentiated carcinoma (SNUC), adenoid cystic carcinoma (ACC), mucosal melanoma, and mucoepidermoid carcinoma. SNUC was defined by histology code 8020 ("carcinoma, undifferentiated type, NOS"). Sarcomas were excluded from the current analysis. We limited our analysis of outcomes by modality to SCCs. Therapy was categorized into the following groups: surgery alone, radiotherapy alone, chemotherapy alone, definitive chemoradiotherapy, surgery with adjuvant radiotherapy, surgery with adjuvant chemoradiotherapy, and neoadjuvant therapy. The neoadjuvant therapy group was defined to include neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy because there were limited numbers of patients available for robust comparison from each individual neoadjuvant approach.
Surgery was defined as site code 30 or higher. For patients who were coded as receiving "debulking" or "surgery, NOS," if the surgical margin was negative or microscopic positive, then the patient was coded as having undergone surgery. If the surgical margin was macroscopic positive or unknown, then the patient was excluded because we were unable to determine whether the surgical procedure was oncologic. Concurrent chemotherapy was defined as a chemotherapy start date within 14 days of the radiotherapy start date. 31 If patients received definitive radiotherapy and received chemotherapy at some point but outside of this 14-day window, they were classified as having received definitive radiotherapy only. Neoadjuvant chemotherapy was defined as starting 7 days before surgery. Adjuvant chemotherapy was defined as starting within 30 days after surgery. Patients not meeting either of these criteria were considered to have undergone surgery alone for primary treatment. Ultimately, very few patients were treated with surgery followed by chemotherapy alone and were excluded from analyses. To categorize patients who received neoadjuvant or adjuvant radiotherapy, we first used the information provided under "RX_SUMM_SURGRAD_SEQ." If this information was not provided, this information then was derived from the days from diagnosis to surgery and the days from diagnosis to radiotherapy. Our initial query as described above was limited to patients' first or second lifetime neoplasm. For our initial analysis, we in addition excluded patients with histologies other than those listed above. This yielded 11,160 patients for our primary analysis. To address the impact of differing treatment modalities, we excluded patients with unknown values for predetermined variables, such as staging and surgical margin status. Patients with distant metastatic disease and those with treatment paradigms other than those described above (or for whom we were unable to define the treatment received) were excluded as well. To account for immortal time bias in this retrospective analysis, we also excluded patients with follow-up of < 2 months. This yielded 3331 patients for the primary MVA in the current study ( Fig. 1 ).
Statistical Analysis
Statistical analyses were performed using SPSS statistical software (version 23.0; IBM Corporation, Armonk, NY). We performed Kaplan-Meier survival analysis with log-rank comparison. Multivariate Cox regression analysis was performed using OS as the outcome with a significance level of P<.05. The proportional hazards assumption was assessed with a test of Schoenfeld residuals for covariates in all final models as previously described, 32 and it returned no significant results. Propensity score matching also was performed for each treatment modality compared with surgery alone. The same variables used in the multivariate analysis were accounted for, including age, sex, CDCC score, race/ ethnicity, year of diagnosis, site, T classification, N classification, facility volume, and surgical margin status. One-to-1 matching without replacement was completed using the nearest neighbor match on the logit of the propensity score for treatment approach with the caliper width set to 0.05 times the standard deviation of the logit of the propensity score, as previously described. 33 Univariate cox hazard ratios (HRs) are reported. Logistic regression models were used to assess the association between patient characteristics and treatment. GraphPad Prism (version 5.03; GraphPad Software Inc, La Jolla, Calif) was used for the creation of the Kaplan-Meier curves presented.
RESULTS
We identified 11,160 patients for our primary analysis inclusive of all patients with known follow-up. The majority of patients were aged 40 to 69 years (60.8%); 59.9% were male and 77.9% were non-Hispanic white. SCC was the most represented histology (54.1% For comparison of treatment modalities, we limited the current study cohort to patients with SCC histology and included only those patients with known values for the predefined variables for MVA, including TNM and overall stage and surgical margin status. We also excluded patients with metastatic disease at the time of diagnosis and those with treatment paradigms other than those of interest and in cases in which the treatment was unable to be defined. Finally, we excluded patients with <2 months follow-up from the current analysis. Using the above criteria, we identified a total of 3331 patients suitable for analysis. In MVA, we found that age (HR, (Table 3) .
DISCUSSION
Sinonasal malignancies present a challenging situation for cancer providers based on their complex anatomic location and the lack of randomized data to guide management. In the current study, we used the NCDB to compile what is to our knowledge the largest study of sinonasal malignancies presented to date. We examined disease prognosis based on histology, subsite, and stage of disease, and assessed outcomes by treatment modality and sequencing for patients with SCC, who comprised the largest subset of patients. Consistent with published retrospective series, the majority of patients presenting with sinonasal cancer were male, were non-Hispanic white, and had squamous cell histology. 5, 9 The results of the current study also demonstrated worse outcomes for African American patients and improved outcomes for Hispanic patients compared with non-Hispanic white patients. It is interesting to note that parallel findings have been shown previously in patients with head and neck cancers, 34 as well as in patients with non-small cell lung cancer and cervical cancer. 35, 36 The majority of patients in the NCDB presented with a high T classification but without lymph node metastases, and only approximately 5% of patients had distant metastatic disease at the time of diagnosis. Such a locally aggressive disease emphasizes the importance of improving local therapy. Local disease recurrence has been reported as a predominant treatment failure pattern in the literature. 5, 17 This also is supported by the findings presented herein that patients with surgically accessible tumors fared better. Patients with tumors of the nasal cavity were found to have far superior OS compared with patients with tumors of other sites. The anatomy of the region, with the proximity of several important structures, adds further complexity to treatment planning. Although both surgical and radiotherapy approaches have advanced in recent years, with endoscopic resections 37 and intensity-modulated radiotherapy, 38,39 we did not see this translate into an improvement in OS over the time period assessed in MVA in the current study. It is likely that we did not observe an improvement in survival over time in the current study because many of these advancements predate our study period.
A recently reported Surveillance, Epidemiology, and End Results (SEER) analysis exclusive to paranasal sinus squamous cell carcinoma showed similar age and race distributions, although higher rates of lymph node metastases compared with our initial analysis inclusive of additional histologies. 40 Patients with mucosal melanoma were found to have the poorest OS, whereas those with esthesioneuroblastoma had the best OS. This finding is consistent with prior studies of mucosal melanoma of the head and neck. 41 The 5-year OS rate (approximately 21%) compared similarly with that reported in other studies of mucosal melanoma. 42 However, a major confounder in this comparison is the mutational analysis and receipt of targeted therapy and immunotherapy. A major limitation of the NCDB is that neither information regarding driver mutations nor any information concerning the receipt of targeted or immunotherapy is available for analysis.
To the best of our knowledge, the optimal therapeutic protocol for patients with sinonasal cancer remains a controversial entity. Although a multimodality approach has been shown to yield improved survival outcomes in some series, [3] [4] [5] [6] [7] [8] the optimal combination and sequencing remain unanswered. In concordance with the literature, the results of the current study demonstrate that Abbreviations: 95% CI, 95% confidence interval; OR (2) margin , odds ratio of having a negative surgical margin; RT, radiotherapy; SCC, squamous cell carcinoma.
radiotherapy alone was inferior to surgery alone 9 and definitive chemoradiation performed similarly to surgery alone. 43 However, patients who received multimodality therapy, in the form of adjuvant radiotherapy, adjuvant chemoradiation, or neoadjuvant therapy, were found to have significantly improved outcomes. This is consistent with some published reports. For example, several series have shown improved survival in patients undergoing surgery and adjuvant radiotherapy or chemoradiotherapy compared with patients receiving radiotherapy alone. 6, 7, 19 Guntinas-Lichius et al demonstrated improved local control and disease-free survival for patients receiving multimodality therapy, including both preoperative and postoperative radiotherapy. 26 Another small series presented by Lee et al showed excellent outcomes in a retrospective cohort of 19 patients treated with induction chemotherapy, surgical resection, and adjuvant radiotherapy or chemoradiotherapy. 8 In all, the findings from these small series are supported by the findings in the current large cancer registry cohort.
The importance of a negative surgical margin has been shown previously 7, 9 and was again demonstrated in the current study. Neoadjuvant chemoradiotherapy was associated with an increased likelihood of achieving a negative surgical margin and neoadjuvant therapy (a group inclusive of neoadjuvant chemotherapy, radiotherapy, or chemoradiation) was associated with improved OS. In a small single-institution case series of neoadjuvant chemoradiotherapy for SNUC, 3 patients achieved a pathologic complete response, 2 patients had negative surgical margins, and another 3 patients had close surgical margins, 44 thereby supporting the benefit of neoadjuvant chemoradiotherapy for surgical margin status. However, it is interesting to note that another small series of patients with SNUC demonstrated no difference in local control or OS based on surgical margin status. 45 As discussed above, the current study supports the use of multimodality therapy for the treatment of these tumors, and we believe the study findings are hypothesis generating. For example, the results herein demonstrate that the addition of radiotherapy to surgery offers an OS benefit either in the neoadjuvant or adjuvant setting, but neither sequence appears to be superior over the other. We suspect that neoadjuvant radiotherapy is preferable in converting patients with unresectable disease to surgical candidates, but outside of that context adjuvant radiotherapy may be preferable given the complexities of operating in a radiated field. Unfortunately, this hypothesis cannot be fully tested in the NCDB due to lack of information regarding initial resectability and surgical complications, but this area of exploration is ripe for prospective assessment. Furthermore, it is not clear that the addition of concurrent chemotherapy to adjuvant radiotherapy further improves OS. This suggests that radiotherapy alone may be sufficient for the sterilization of microscopic disease for SCC in this setting. However, there is a key oncologic outcome that we were unable to assess with the NCDB: freedom from distant metastases. It is possible that chemotherapy improves freedom from distant metastases even if that does not translate into an OS benefit. This may be an important indication for chemotherapy and should be tested prospectively as well.
Overall, to the best of our knowledge, the majority of prior studies regarding this topic consist of small cohorts or case series. Some of these studies failed to demonstrate an advantage to multimodality therapy, [9] [10] [11] whereas others demonstrated improved survival outcomes, which is consistent with the findings of the current study. [3] [4] [5] [6] [7] [8] One reason that earlier studies might have failed to demonstrate an improvement with multimodality therapy may be the radiotherapy techniques used, compared with the modern cohort of patients in the current study. Although another more contemporary national cancer registry study also did not demonstrate a benefit to adjuvant radiotherapy, 1 it does not appear that this study accounted for other confounding variables. Such outcomes may simply be the result of selection bias because patients with more advanced disease are likely to be offered more extensive therapy. It is important to note that we ultimately may have prospective data to help guide management because there currently are 2 ongoing Italian trials addressing multimodality therapy for sinonasal malignancies (ClinicalTrials.gov NCT02099175 and NCT02099188). 46, 47 Nevertheless, for now, this large cancer registry cohort offers valuable information to help guide treatment decisions for these difficult cases.
The current study has limitations. It is important to note that the NCDB does not provide data regarding cause-specific survival. Furthermore, because it is a retrospective study, the results of the current study were prone to contamination by other factors for which we could not account. To mitigate as much confounding bias as possible herein, we used MVA and propensity score matching to account for available important variables. Furthermore, to reduce the contribution of immortal time bias, specifically within the context of our neoadjuvant therapy outcomes, we excluded all patients with <2 months of follow-up. Ultimately, we favor this approach but it is important to note that by excluding patients with short follow-up, we also may be selecting for patients who survive aggressive therapies. To better understand the influence of excluding patients with <2 months follow-up, we performed a separate analysis inclusive of all patients and found no significant changes in the results (see Supporting Information Table 2 ). Another concern is that there is a subset of patients treated nonoperatively, but from the data provided in the NCDB, we cannot know whether these patients presented with resectable or unresectable disease, or the decision-making process that led to them being managed nonoperatively. Despite these limitations, the current study is a large study that asked pointed questions regarding specific treatment modalities to offer cancer providers additional information to help navigate the complex decision making involved in the management of patients with these rare diseases.
Conclusions
Herein we present what is to our knowledge the largest study to date of sinonasal malignancies. We demonstrated an advantage of multimodality therapy even when accounting for surgical margin status. Overall, these data emphasize the importance of coordinated multidisciplinary care in the management of patients with sinonasal malignancies.
FUNDING SUPPORT
No specific funding was disclosed. 
CONFLICT OF INTEREST DISCLOSURES

